SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Price, Forecast & Analysis
USA - NASDAQ:SONN - US83548R4020 - Common Stock
SONN Key Statistics, Chart & Performance
The current stock price of SONN is 5.92 USD. In the past month the price increased by 63.09%. In the past year, price increased by 96.03%.
SONN Latest News, Press Relases and Analysis
SONN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About SONN
Company Profile
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Company Info
SONNET BIOTHERAPEUTICS HOLDI
100 Overlook Center, Suite 102
Princeton NEW JERSEY 08540 US
CEO: Pankaj Mohan
Employees: 13
Phone: 16093752227
SONNET BIOTHERAPEUTICS HOLDI / SONN FAQ
Can you describe the business of SONNET BIOTHERAPEUTICS HOLDI?
Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The company went IPO on 2005-07-27. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The firm's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The firm is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).
Can you provide the latest stock price for SONNET BIOTHERAPEUTICS HOLDI?
The current stock price of SONN is 5.92 USD. The price increased by 9.63% in the last trading session.
Does SONNET BIOTHERAPEUTICS HOLDI pay dividends?
SONN does not pay a dividend.
What is the ChartMill rating of SONNET BIOTHERAPEUTICS HOLDI stock?
SONN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
How many employees does SONNET BIOTHERAPEUTICS HOLDI have?
SONNET BIOTHERAPEUTICS HOLDI (SONN) currently has 13 employees.
Who owns SONNET BIOTHERAPEUTICS HOLDI?
You can find the ownership structure of SONNET BIOTHERAPEUTICS HOLDI (SONN) on the Ownership tab.
What is the outstanding short interest for SONNET BIOTHERAPEUTICS HOLDI?
The outstanding short interest for SONNET BIOTHERAPEUTICS HOLDI (SONN) is 33.46% of its float.
SONN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to SONN. When comparing the yearly performance of all stocks, SONN is one of the better performing stocks in the market, outperforming 95.94% of all stocks.
SONN Financial Highlights
Over the last trailing twelve months SONN reported a non-GAAP Earnings per Share(EPS) of -7.23. The EPS increased by 70.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -659.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
SONN Forecast & Estimates
7 analysts have analysed SONN and the average price target is 20.4 USD. This implies a price increase of 244.59% is expected in the next year compared to the current price of 5.92.